Novo Nordisk and Pfizer Increase Offers for Biotech Firm Metsera

In a competitive bid to acquire the biotech company Metsera, which specializes in obesity medications, pharmaceutical giants Novo Nordisk and Pfizer have both enhanced their offers. This development was confirmed by Metsera on Tuesday.

Novo Nordisk's new proposal values Metsera at approximately $10 billion. Meanwhile, Pfizer has increased its bid to $8.1 billion. A significant aspect of Novo Nordisk's offer includes an additional cash payment of $24 per share if Metsera achieves certain milestones in drug development and approval, up from the previous offer of $22.50 per share.

The acquisition battle has also moved into the legal arena. Pfizer has filed lawsuits against Metsera, its board, and Novo Nordisk. In one of the lawsuits filed last Friday, Pfizer argues that Novo Nordisks bid violates a merger agreement between Pfizer and Metsera. Furthermore, Pfizer accuses Novo Nordisk of attempting to bypass antitrust reviews. The pharmaceutical company is seeking court intervention to prevent Metsera from canceling the agreement.

Pfizer's interest in Metsera is driven by strategic motives. Without its own weight-loss drug, Pfizer is eager to tap into the lucrative $150 billion obesity market. The acquisition would also help Pfizer offset declining revenues from its COVID-19 business and address challenges posed by expiring patents. The outcome of this bidding war remains uncertain, but it highlights the increasing value and competition in the biotech sector, particularly in areas addressing global health challenges like obesity.